Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Study of Everolimus (RAD001) in Combination With Lenalidomide in Patients With Advanced Solid Malignancies Enriched for Renal Cell Carcinoma

NCT01218555 is registered in ClinicalTrials.gov with Emory University as lead sponsor.

NCT NCT01218555
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01218555 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Study of Everolimus (RAD001) in Combination With Lenalidomide in Patients With Advanced Solid Malignancies Enriched for Renal Cell Carcinoma
Lead sponsor
Emory University
Phase
Phase 1
Overall status
Completed
Start date
September 9, 2010
Completion date
November 5, 2020
Enrollment
44 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

adenoidcystic carcinoma, neuroendocrine tumors, solid organ malignancies